ACLS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gelman, B.
Right arrow Articles by Silverman, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gelman, B.
Right arrow Articles by Silverman, L.
Annals of Clinical and Laboratory Science, Vol 18, Issue 1, 46-52
Copyright © 1988 by Association of Clinical Scientists


Articles

Cerebrospinal fluid and plasma apolipoproteins in patients with multiple sclerosis

BB Gelman, N Rifai, RH Christenson, and LM Silverman

Apolipoprotein (apo) E is synthesized by cells of the central and peripheral nervous systems, and its synthesis and secretion in the peripheral nervous systems, and its synthesis and secretion in the peripheral nervous system of animals are greatly stimulated following Wallerian degeneration. It has been suggested that apo E functions in the metabolism of myelin lipids, but its physiologic role in nervous tissue has not been elucidated. To determine if apo E might play a role in demyelinating neuropathy, the concentrations were examined of apos E and A-1 in the cerebrospinal fluid (CSF) and plasma of patients with multiple sclerosis during clinical remission, and in patients with no neurologic disease. Serum and CSF albumin concentrations were measured to account for the possible influences of serum apo E concentration and/or altered blood-brain barrier permeability on the CSF apo E pool. A CSF index for apo E and apo A-1 was calculated in the same manner presently used for calculation of immunoglobulin G (IgG) production in the nervous system of patients with multiple sclerosis (MS). The results showed that the concentrations of apo E, apo Al, and albumin in the CSF of the MS patients were not significantly altered. The concentration of apo E in the serum, however, was significantly (p less than 0.001) decreased by 44 percent in the MS patients. The difference was relatively specific for serum apo E because the serum apo Al and albumin concentrations were unchanged.(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:


Home page
Clin. Chem.Home page
K. Yamauchi, M. Tozuka, T. Nakabayashi, M. Sugano, H. Hidaka, Y. Kondo, and T. Katsuyama
Apolipoprotein E in Cerebrospinal Fluid: Relation to Phenotype and Plasma Apolipoprotein E Concentrations
Clin. Chem., April 1, 1999; 45(4): 497 - 504.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
J. Jordan, M. F. Galindo, R. J. Miller, C. A. Reardon, G. S. Getz, and M. J. LaDu
Isoform-Specific Effect of Apolipoprotein E on Cell Survival and beta -Amyloid-Induced Toxicity in Rat Hippocampal Pyramidal Neuronal Cultures
J. Neurosci., January 1, 1998; 18(1): 195 - 204.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
R. Schmidt, H. Schmidt, F. Fazekas, M. Schumacher, K. Niederkorn, P. Kapeller, V. Weinrauch, and G. M. Kostner
Apolipoprotein E Polymorphism and Silent Microangiopathy-Related Cerebral Damage : Results of the Austrian Stroke Prevention Study
Stroke, May 1, 1997; 28(5): 951 - 956.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1988 by the Association of Clinical Scientists.